ACPU
BPMC

Arrowgrass Capital Partners (US)’s Blueprint Medicines BPMC Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-26,234
Closed -$1.98M – 185
2017
Q4 		$1.98M Buy
+26,234
New +$1.85M 0.02% 389
2015
Q3 		– Sell
-42,588
Closed -$1.13M – 465
2015
Q2 		$1.13M Buy
+42,588
New +$1.22M 0.02% 400

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s BPMC Position: Q1 2018 in Review

Arrowgrass Capital Partners (US) sold out of Blueprint Medicines (BPMC) in Q1 2018, closing a stake of 26,234 shares — an estimated $1.98M sold.

Arrowgrass Capital Partners (US) first reported a position in BPMC in Q2 2015 and held it in 2 quarters. The position peaked at $1.98M in Q4 2017. 175 funds tracked by Wall St. Rank hold BPMC as of Q1 2018.

  • Arrowgrass Capital Partners (US) reported no remaining Blueprint Medicines position as of Q1 2018 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 26,234 Blueprint Medicines shares in Q1 2018, an estimated $1.98M.
  • Arrowgrass Capital Partners (US) first reported a position in Blueprint Medicines in Q2 2015 and held it in 2 quarters.
  • Arrowgrass Capital Partners (US)'s Blueprint Medicines position peaked at $1.98M in Q4 2017.
  • 175 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2018.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q1 2018, filed 15 May 2018.